14 June 2019 - - US-based biotechnology company Seattle Genetics, Inc. (NASDAQ: SGEN) is presenting data from its Adcetris (brentuximab vedotin) clinical development programme at the 24th Annual Congress of the European Hematology Association taking place June 13-16 in Amsterdam; and the International Conference on Malignant Lymphoma from June 18-22 in Lugano, the company said.
Updated analyses from clinical trials evaluating Adcetris in combination with Opdivo (nivolumab), as well as encore analyses from the phase 3 ECHELON-1, ECHELON-2 and ALCANZA clinical trials, will be highlighted in 12 presentations at EHA and ICML.
Adcetris is an antibody-drug conjugate directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas. 
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to harness the body's own immune system to help restore anti-tumor immune response.
Adcetris and Opdivo are not approved in combination for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma, HL, pediatric HL or for other indications. Adcetris in combination with bendamustine is not approved for HL.
Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercialises transformative therapies targeting cancer to make a meaningful difference in people's lives.
Adcetris (brentuximab vedotin) utilizes the company's industry-leading antibody-drug conjugate technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.
Beyond Adcetris, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors.
Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.
Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer.
In addition, it is leveraging expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.
The company is headquartered in Bothell, Washington, and has a European office in Switzerland.